Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Immunization Strategy 2017-2022


Foreword
 
There have been many transformations to the NIP inthe recent years. New vaccines wereadded to the vaccination schedule, the cohorts served by the public sector kepton expandingsince the onset of the Syrian crisis, measures to consolidatethe vaccine purchasing arrangements were adopted,and there wasa leveraging up ofthe vaccinovigilanceand its effective management.In 2016, the Ministryof health in Lebanon decided that it was the time to take stock, constructon the current NIP strengthsand achievements andidentify areas for further improvement. A strategy for the NIP for 2016-2020 wasenvisagedin agreementwith the development partners. A detailed situation analysis assessment was initiatedin October 2015 in two stages: at the initial stage, the country and health system contexts were analyzed, and immunization system performance was measured. In the second stage, a framework was developed in consultations with key stakeholders to define gaps in the evidence. Immunization coverage evaluation survey was conducted in 2016 and fed into filling the lacunas in information.

The present document expresses the country vision, goals and priorities of the national immunization program. It relies on a careful examination of the situation analysis, an assessment of the enablers and challenges facing the immunization services and defines the national immunization strategies addressing these contests. The strategies were formulated as informed choices across more than one solution deemed most feasible and efficient considering the country context.

The document is structured in three sections:

Section 1“Situational analysis” presents briefly the organization and operation of the national immunization program as well as the recent achievements and remaining challenges,

Section 2 “Conceptual framework” describes the future vision of the country in regards to vaccine preventable diseases, the long term goals to be achieved and the more specific results –immunization system objectives and targets for 2020,

Section 3 defines the Strategies to address the bottlenecks and achieve immunization system objectives by 2020. Most of strategies (so called “immunization system specific” ones) are presented by relevant health system blocks.The focus of the NIP Strategy, is to assistthe MOPH to meet international goals set by the World Health Organization (WHO) under the Global Immunization Vision and Strategy (GIVS). The Strategy articulates action areas to conserve the successful achievements of the last years, built on the current favoring momentum and propose solutions for the drawbacks

The Strategy comprises nineStrategic Priority Areas to complement and strengthen the NIP.

The matrix (Figure 2) in Annexesshows expected results of the immunization system development strategies by health system building blocks and links them to the root causes (weaknesses and treats) identified during the system analysis...
    ...
    12
    ...
ATC Name B/G Ingredients Dosage Form Price
A16AB02 CEREZYME B Imiglucerase - 400IU 400IU Injectable lyophilised powder for solution L.L
J01DD08 CEFIX G Cefixime (trihydrate) - 400mg 400mg Capsule 791,523 L.L
J01DD08 CEFDIA G Cefixime - 400mg 400mg Tablet, film coated 806,306 L.L
J05AB01 CYCLOVEX G Aciclovir - 400mg 400mg Tablet, scored 2,687,685 L.L
L01EA01 CEMIVIL G Imatinib - 400mg 400mg Tablet, film coated 41,106,321 L.L
G03DA04 CYCLOGEST G Progesterone - 400mg 400mg Pessary 1,546,763 L.L
M01AE01 CAPTAIN FORTE G Ibuprofen - 400mg 400mg Capsule, soft gelatin 508,740 L.L
J01MA02 CIPROFLOXACINE PANPHARMA G Ciprofloxacine (HCl) - 400mg/200ml 400mg/200ml Injectable solution 9,908,924 L.L
J01MA02 CEFLOXINE G Ciprofloxacin - 400mg/200ml 400mg/200ml Injectable solution 1,134,203 L.L
J01MA02 CIPROFLOXACINE PANPHARMA G Ciprofloxacine (HCl) - 400mg/200ml 400mg/200ml (2mg/ml) Injectable solution 9,908,924 L.L
D10BA01 CURACNE G Isotretinoin - 40mg 40mg Capsule, soft gelatin 3,553,120 L.L
D10BA01 CONTRACNE ISOTRETINOINE G Isotretinoin - 40mg 40mg Capsule, soft 3,043,803 L.L
D10BA01 CURACNE G Isotretinoin - 40mg 40mg Capsule, soft gelatin 3,553,120 L.L
C10AA07 CRESTOR B Rosuvastatin (calcium) - 40mg 40mg Tablet, film coated 804,962 L.L
L01EX07 CABOMETYX B Cabozantinib - 40mg 40mg Tablet, film coated 401,478,618 L.L
L04AB04 CINNORA BioTech Adalimumab - 40mg/0.8ml 40mg/0.8ml Injectable solution 14,817,734 L.L
G03GA05 CINNAL-f BioHuman Follitropin alfa - 450IU/0.75ml 450IU/0.75ml Injectable solution 7,372,177 L.L
C01DX12 CORVASAL 4MG B Molsidomine - 4mg 4mg Tablet 492,742 L.L
C02CA04 CARDULAR B Doxazosin (mesylate) - 4mg 4mg Tablet 755,239 L.L
C02CA04 CURCARD G Doxazosin (mesylate) - 4mg 4mg Tablet 452,875 L.L
D06BA02 CREM-O-SULFA G Sulfathiazole - 5% 5% Cream 202,216 L.L
D06BB03 CIVAR G Aciclovir - 5% 5% Cream 507,972 L.L
G03GA01 CHORIOMON BioHuman Human Chorionic Gonadotrophin - 5,000IU 5,000IU Injectable lyophilised powder for solution+diluent 4,031,528 L.L
B03BA01 COBAL G Vitamin B12 - 500mcg 500mcg Tablet, coated 486,471 L.L
B03BA05 COBAL G Mecobalamine - 500mcg/ml 500mcg/ml Injectable solution 1,128,828 L.L
L01BC06 CAPECITABINE ACCORD G Capecitabine - 500mg 500mg Tablet, film coated 10,908,012 L.L
L01BC06 CAPECITABINE BIOGARAN G Capecitabine - 500mg 500mg Tablet, coated 12,123,049 L.L
L01BC06 CAPECITABINE NEAPOLIS G Capecitabine - 500mg 500mg Tablet, film coated 11,222,829 L.L
L01BC06 CAPECITABINE GP PHARM G Capecitabine - 500mg 500mg Tablet, film coated 8,869,508 L.L
L01BC06 CAPEDA G Capecitabine - 500mg 500mg Tablet, film coated 4,927,423 L.L
    ...
    12
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025